Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Márton KalabayDepartment of Genetics, Cell- and Immunobiology, Faculty of Medicine, Semmelweis University, Nagyvárad Square 4, 1085 Budapest, Hungary.
Zsófia SzászDepartment of Genetics, Cell- and Immunobiology, Faculty of Medicine, Semmelweis University, Nagyvárad Square 4, 1085 Budapest, Hungary.ORCID 0009-0000-3110-0379
Eszter LajkóDepartment of Genetics, Cell- and Immunobiology, Faculty of Medicine, Semmelweis University, Nagyvárad Square 4, 1085 Budapest, Hungary.ORCID 0000-0002-4796-4646
Bálint BaguDepartment of Genetics, Cell- and Immunobiology, Faculty of Medicine, Semmelweis University, Nagyvárad Square 4, 1085 Budapest, Hungary.
Éva PállingerDepartment of Genetics, Cell- and Immunobiology, Faculty of Medicine, Semmelweis University, Nagyvárad Square 4, 1085 Budapest, Hungary.
Cintia DuróDepartment of Inorganic Chemistry, Faculty of Chemistry, Eötvös Loránd University, Egyetem Square 1-3, 1053 Budapest, Hungary.
Tamás JerneiDepartment of Inorganic Chemistry, Faculty of Chemistry, Eötvös Loránd University, Egyetem Square 1-3, 1053 Budapest, Hungary.ORCID 0000-0003-4990-4281
Antal CsámpaiDepartment of Inorganic Chemistry, Faculty of Chemistry, Eötvös Loránd University, Egyetem Square 1-3, 1053 Budapest, Hungary.ORCID 0000-0003-2107-7309
Angéla TakácsDepartment of Genetics, Cell- and Immunobiology, Faculty of Medicine, Semmelweis University, Nagyvárad Square 4, 1085 Budapest, Hungary.ORCID 0000-0002-8912-8216
László KőhidaiDepartment of Genetics, Cell- and Immunobiology, Faculty of Medicine, Semmelweis University, Nagyvárad Square 4, 1085 Budapest, Hungary.ORCID 0000-0002-9002-0296
Funding
Ministri of Innovation and Technology EFOP-3.6.3-VEKOP-16-2017-00009Ministry of Innovation and Technology ÚNKP-22-3-II-SE-77 and ÚNKP-21-2-SE-35National Research, Development and Innovation Office NVKP_16-1-2016-0036
6 · The paper itself
Abstract
Tamoxifen is a well-established selective estrogen receptor modulator (SERM) widely used in breast cancer treatment, yet its efficacy varies across tumor types. To enhance its antitumor potential, we previously synthesized and investigated novel ferrocene-linked (T5, T15) derivatives. This publication is a close continuation of this work, introducing a new indene-based (T6) derivative.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Comparative Study of Ferrocene- and Indene-Based Tamoxifen Derivatives of Different Molecular Flexibility on High-Mortality Cancer Cell Lines. · full record | OpenQuestion